Europe Tetanus Toxoid Vaccine Market Size & Outlook
Related Markets
Europe tetanus toxoid vaccine market highlights
- The Europe tetanus toxoid vaccine market generated a revenue of USD 1,336.8 million in 2024.
- The market is expected to grow at a CAGR of 5.5% from 2025 to 2030.
- In terms of segment, diphtheria,tetanus, and pertussis (dtap) was the largest revenue generating vaccine in 2024.
- Diphtheria and Tetanus (DT) is the most lucrative vaccine segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 1,336.8 million |
| Market revenue in 2030 | USD 1,843.6 million |
| Growth rate | 5.5% (CAGR from 2025 to 2030) |
| Largest segment | Diphtheria,tetanus, and pertussis (dtap) |
| Fastest growing segment | Diphtheria and Tetanus (DT) |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diphtheria,Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT) |
Other key industry trends
- In terms of revenue, Europe region accounted for 23.0% of the global tetanus toxoid vaccine market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,875.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Tetanus Toxoid Vaccine Market Scope
Tetanus Toxoid Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Grifols, S.A. | View profile | - | - | - |
| Merck & Co., Inc. | View profile | - | - | - |
| Pfizer Inc. | View profile | - | - | - |
| Abbott | View profile | - | - | - |
| Emergent BioSolutions Inc | View profile | 1600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | https://www.emergentbiosolutions.com |
| CEVA Inc | View profile | 424 | 15245 Shady Grove Road, Suite 400, Rockville, MD, United States, 20850 | https://www.ceva-dsp.com |
| Virbac SA | View profile | 5400 | 2065m LID, 1 ere avenue, Carros, France, 06516 | https://www.virbac.com |
| Zoetis Inc Class A | View profile | 14100 | 10 Sylvan Way, Parsippany, NJ, United States, 07054 | https://www.zoetis.com |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
Europe tetanus toxoid vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to tetanus toxoid vaccine market will help companies and investors design strategic landscapes.
Diphtheria,tetanus, and pertussis (dtap) was the largest segment with a revenue share of 64.21% in 2024. Horizon Databook has segmented the Europe tetanus toxoid vaccine market based on diphtheria,tetanus, and pertussis (dtap), diphtheria and tetanus (dt) covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Europe tetanus toxoid vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe tetanus toxoid vaccine market databook
-
Our clientele includes a mix of tetanus toxoid vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe tetanus toxoid vaccine market , including forecasts for subscribers. This continent databook contains high-level insights into Europe tetanus toxoid vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe tetanus toxoid vaccine market size, by country, 2018-2030 (US$M)
Europe Tetanus Toxoid Vaccine Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
